Markets

“KALA BIO, Inc. Reports Third Quarter 2023 Financial Results and Provides Corporate Update\n\nArlington, Mass., November 13, 2023 – KALA BIO, Inc. (NASDAQ:KALA), a clinical-stage biopharmaceutical company, announced its financial results for the third quarter ended September 30, 2023, and provided a corporate update.\n\n”We continue to make progress on our corporate priorities”, said Mark Iwicki, Chair and Chief Executive Officer of KALA BIO. “We are actively enrolling patients in our CHASE Phase 2b trial of KPI-012 for PCED and are targeting topline safety and efficacy data in the second half of 2024. In addition, we are advancing our MSC-S pipeline and exploring opportunities to expand KPI-012 into additional corneal indications. We are also evaluating the potential of our MSC-S platform for inherited retinal degenerative diseases and other back-of-the-eye applications. We remain committed to maximizing the potential of our cell-free, regenerative approach to treating rare and severe ocular surface and retinal diseases”.\n\nKPI-012 is a mesenchymal stem cell secretome (MSC-S) that combines growth factors, protease inhibitors, matrix proteins, and neurotrophic factors to potentially correct impaired corneal healing, which is an underlying cause of multiple severe ocular diseases. The company believes the multifactorial mechanism of action of its MSC-S program makes it a platform technology and is evaluating its potential for multiple rare, front

“KALA BIO, Inc. Reports Third Quarter 2023 Financial Results and Provides Corporate Update\n\nArlington, Mass., November 13, 2023 – KALA BIO, Inc. (NASDAQ:KALA), a clinical-stage biopharmaceutical company, announced its financial results for the third quarter ended September 30, 2023, and provided a corporate update.\n\n”We continue to make progress on our corporate priorities”, said Mark Iwicki, Chair and Chief Executive Officer of KALA BIO. “We are actively enrolling patients in our CHASE Phase 2b trial of KPI-012 for PCED and are targeting topline safety and efficacy data in the second half of 2024. In addition, we are advancing our MSC-S pipeline and exploring opportunities to expand KPI-012 into additional corneal indications. We are also evaluating the potential of our MSC-S platform for inherited retinal degenerative diseases and other back-of-the-eye applications. We remain committed to maximizing the potential of our cell-free, regenerative approach to treating rare and severe ocular surface and retinal diseases”.\n\nKPI-012 is a mesenchymal stem cell secretome (MSC-S) that combines growth factors, protease inhibitors, matrix proteins, and neurotrophic factors to potentially correct impaired corneal healing, which is an underlying cause of multiple severe ocular diseases. The company believes the multifactorial mechanism of action of its MSC-S program makes it a platform technology and is evaluating its potential for multiple rare, front- and back-of-the-eye diseases.\n\nKALA is actively enrolling patients in the primary safety and efficacy portion of the CHASE (Corneal Healing After SEcretome therapy) Phase 2b clinical trial evaluating KPI-012 for the treatment of Persistent Corneal Epithelial Defect (PCED). This condition is a persistent, non-healing corneal defect or wound that is refractory to conventional treatments and can lead to significant infection, corneal perforations, scarring, and vision loss. KALA is targeting to announce topline data in the second half of 2024. If the results are positive, and subject to discussion with regulatory authorities, KALA believes the CHASE Phase 2b trial could serve as the first of two pivotal trials to support the submission of a Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) for KPI-012.\n\nKALA is also evaluating the potential development of KPI-012 for additional rare, front-of-the-eye diseases, such as Limbal Stem Cell Deficiency and other corneal diseases that threaten vision.\n\nKALA has initiated preclinical studies for its KPI-014 program, evaluating the utility of its MSC-S platform for inherited retinal degenerative diseases such as Retinitis Pigmentosa and Stargardt Disease.\n\nFinancial Results:\n\nAs of September 30, 2023, KALA had cash and cash equivalents of $56.1 million, compared to $70.5 million as of December 31, 2022. This decrease reflects cash used in operations and a $2.5 million milestone payment to the former Combangio, Inc. (Combangio) shareholders following the dosing of the first patient in the CHASE trial, as well as a prepayment of approximately $10.0 million in principal and fees under KALA’s loan agreement, partially offset by net proceeds of $18.0 million raised under KALA’s at-the-market offering program. Based on its current plans, KALA anticipates that its cash resources as of September 30, 2023, together with anticipated remaining funding under the CIRM award, will enable it to fund operations into the second quarter of 2025.\n\nIn a KALA BIO, Inc. Continues to make progress on its corporate priorities, with enrollment ongoing in the CHASE Phase 2b clinical trial of KPI-012 for PCED and topline data expected in the second half of 2024.”$KALA2023-12-14T14:15:44.556Z

Related Articles

Leave a Reply

Your email address will not be published. Required fields are marked *

Back to top button